Generics

  • Teva launches generic version of popular antidepressant

    NORTH WALES, Pa. Teva Pharmaceutical Industries has launched a generic version of a weekly formulation of a popular antidepressant, the generic drug maker said.

     

    Teva announced the launch of fluoxetine delayed-release capsules, a generic version of Eli Lilly’s Prozac Weekly.

     

    NORTH WALES, Pa. Teva Pharmaceutical Industries has launched a generic version of a weekly formulation of a popular antidepressant, the generic drug maker said.

     

  • Teva introduces generic drug that lowers blood pressure

    NORTH WALES, Pa. Teva Pharmaceutical Industries has introduced a generic drug for lowering patients’ blood pressure, the world’s largest manufacturer of generic drugs said Monday.

    Teva introduced clonidine transdermal system, a generic version of Boehringer Ingelheim’s Catapres-TTS. The drug is available in 0.1 mg, 0.2 mg and 0.3 mg strengths and comes in the form of a patch designed for daily application.

    The drug has annual sales of around $297 million, according to IMS Health.

  • Mylan markets generic Solodyn ER

    PITTSBURGH Mylan has launched a generic treatment for acne, the company said Thursday.

    Mylan announced the launch of minocycline hydrochloride extended-release tablets in the 45 mg, 90 mg and 135-mg strengths. The drug is a generic version of Solodyn ER, made by Medicis Pharmaceuticals Corp.

     

    Minocycline ER had sales of around $496 million during the 12-month period ended in March, according to IMS Health.

     

  • Sandoz first to receive FDA approval for Lovenox generic

    SILVER SPRING, Md. The Food and Drug Administration has approved the first generic version of a Sanofi-Aventis injected drug used to treat deep vein thrombosis, the agency said Friday.

     

    The FDA approved generic enoxaparin sodium, a version of Sanofi’s Lovenox, developed under a collaboration between Momenta Pharmaceuticals and Sandoz, the generics division of Swiss drug maker Novartis.

     

     

  • GPhA: Generic drug utilization can curb wasteful Medicaid spending

    WASHINGTON A reported excess of a quarter billion dollars is a good case for increasing use of generic drugs under the Medicaid program, according to the main lobby for the generic drug industry.

     

    Responding to a report by conservative think tank the American Enterprise Institute that identified $271 million in wasteful Medicaid spending, the Generic Pharmaceutical Association said it was a “compelling case” for increasing generic drug utilization.

     

     

  • FDA approves additional strengths of Actavis' generic Wellbutrin SR

    MORRISTOWN, N.J. Actavis has received regulatory approval from the Food and Drug Administration for a generic antidepressant, the drug maker announced Wednesday.

    Actavis said it immediately will begin distributing its bupropion HCl extended-release (SR) tablets in 100-mg and 200-mg strengths. The drug is the generic equivalent of GlaxoSmithKline's Wellbutrin SR. Actavis already has marketed generic Wellbutrin SR in the 150-mg strength. The drug maker received approval in March 2008.

  • Caraco launches generic Wellbutrin SR

    DETROIT Generic drug maker Caraco Pharmaceutical Labs has launched a generic antidepressant, Caraco said Wednesday.

     

    The drug maker announced the launch of bupropion hydrochloride extended-release tablets in the 150 mg and 200 mg strengths.

     

     

    The drug is a generic version of GlaxoSmithKline’s Wellbutrin SR. Various versions of the drug have annual sales of $300 million, according to Caraco.

     

  • Mylan gets green light for generic hypertension treatment

    PITTSBURGH Mylan subsidiary Mylan Technologies has received final approval from the Food and Drug Administration for its hypertension treatment, the generic drug maker said.

    Mylan said its clonidine transdermal system USP was approved in the 0.1 mg/day, 0.2 mg/day and 0.3 mg/day strengths. Mylan's CTS is the generic version of Boehringer Ingelheim's Catapres-TTS.

     

  • Teva launches generic Amerge

    NORTH WALES, Pa. Teva Pharmaceuticals has launched a drug for treating migraine headaches, the generic drug maker said.

     

    Teva announced the launch of naratriptan tablets in the 1 mg and 2.5-mg strengths. The tablets are a generic version of GlaxoSmithKline’s Amerge. The drug is used to treat acute migraine attacks in adults with or without visual disturbances preceding the attacks known as aura.

     

     

  • Mylan's generic arthritis drug receives FDA approval

    PITTSBURGH The Food and Drug Administration has approved a generic arthritis treatment made by Mylan, the drug maker said Wednesday.

     

    The FDA approved nabumetone tablets, a treatment for osteoarthritis and rheumatoid arthritis, in the 500 mg and 750-mg strengths.

     

     

X
This ad will auto-close in 10 seconds